These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 11219554)

  • 1. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations].
    Milsom I; Odlind V; von Schoultz B; Ostlund I; Persson E
    Lakartidningen; 2002 Jan; 99(1-2):10-2, 15. PubMed ID: 11871161
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral contraceptives and venous thromboembolism: an epidemiological review.
    Lidegaard O
    Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What does the micropill bring?].
    Mall-Haefeli M
    Ther Umsch; 1986 May; 43(5):365-71. PubMed ID: 2941889
    [No Abstract]   [Full Text] [Related]  

  • 9. Third generation oral contraceptives containing desogestrel and gestodene and the risk of thrombosis.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1996 Mar; 15(1):5-7. PubMed ID: 8920631
    [No Abstract]   [Full Text] [Related]  

  • 10. [Third-generation oral contraceptives--how big is the risk of venous thrombosis?].
    Iversen OE
    Tidsskr Nor Laegeforen; 2004 Jun; 124(11):1521-2. PubMed ID: 15195157
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
    Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
    Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
    Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
    [No Abstract]   [Full Text] [Related]  

  • 16. [Third generation oral contraceptives and risk of venous thrombosis].
    Olsen J
    Ugeskr Laeger; 2002 Jan; 164(3):346. PubMed ID: 11816336
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
    Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
    Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis?
    Sapp AV; Lindbloom EJ
    J Fam Pract; 2001 Oct; 50(10):893. PubMed ID: 11674894
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA; Dinger JC; Assmann A; Minh TD
    Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of venous thromboembolism with third-generation oral contraceptives: A review.
    Weiss G
    Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 2):295-301. PubMed ID: 9988833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.